In 2025, the Milner Therapeutics Institute, together with Cambridge University Health Partners, announced a collaboration with Flagship Pioneering – a scientific innovation engine for transformative platforms and products in human health, sustainability, and beyond. Flagship Pioneering – based in Cambridge, Massachusetts – opened its UK hub in 2023, and launched its first UK-based company, Quotient Therapeutics, the same year. Quotient Therapeutics draws on strengths from both sides of the Atlantic to advance its somatic genomics research and unlock new ways to transform medicine and tackle complex diseases. The collaboration between Milner Therapeutics Institute, Cambridge University Health Partners, and Flagship Pioneering brings together Flagship’s ecosystem of more than 40 life sciences companies – including Quotient – with Cambridge researchers and clinicians, with a shared ambition to accelerate biotech research and innovation.
One year on, we can reflect on the progress made. What began as a shared set of ambitions has now evolved into new partnerships and several live discussions around key research topics – from synthetic lethality in oncology, pre-emptive metabolic medicine and new modalities, to new opportunities around clinical training and improved access to patient tissue and data.
It has been exciting to learn more about Flagship’s unique model of company and platform creation, and to bring this expertise and passion into the Cambridge ecosystem through visits from UK and US colleagues across the Flagship portfolio and through the support of entrepreneurial initiatives such as the Cambridge NeuroWorks programme. We look forward to seeing how the numerous connections made continue to evolve into impactful partnerships that can advance therapeutic discovery.
